OTLK
Outlook Therapeutics, Inc. NASDAQ$0.26
Mkt Cap $10.8M
52w Low $0.16
3.1% of range
52w High $3.39
50d MA $0.32
200d MA $1.12
P/E (TTM)
-0.1x
EV/EBITDA
-0.9x
P/B
—
Debt/Equity
-0.9x
ROE
266.8%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
0.19
50d MA
$0.32
200d MA
$1.12
Avg Volume
3.1M
About
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Out…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | -0.17 | -0.22 | -29.4% | 0.42 | +1.0% | -3.0% | +2.9% | -2.2% | -5.3% | -2.7% | -20.4% | — |
| Dec 19, 2025 | AMC | -0.26 | -0.22 | +15.4% | 2.01 | +1.0% | -8.5% | -7.5% | -9.0% | -9.5% | -1.5% | -74.1% | — |
| Aug 14, 2025 | AMC | -0.42 | -0.44 | -4.8% | 2.43 | +2.9% | -3.7% | +14.0% | +8.2% | -1.6% | -0.8% | -56.8% | — |
| May 15, 2025 | AMC | -0.55 | -0.40 | +27.3% | 1.68 | +1.2% | +4.2% | +4.8% | +1.2% | -3.0% | -2.4% | +5.4% | — |
| Feb 14, 2025 | AMC | -0.85 | -0.89 | -4.7% | 1.87 | -1.1% | -8.6% | -9.1% | -12.3% | -16.6% | -18.7% | -17.6% | — |
| Dec 27, 2024 | AMC | -0.83 | -0.77 | +7.2% | 2.01 | -2.0% | -7.5% | -6.0% | +2.5% | +11.4% | +17.9% | -6.5% | — |
| Aug 14, 2024 | AMC | -1.06 | -0.83 | +21.7% | 7.34 | +1.5% | +4.6% | +5.0% | -2.5% | -3.3% | -1.0% | -11.9% | — |
| May 15, 2024 | AMC | -0.88 | -1.55 | -76.1% | 7.43 | -3.9% | -1.3% | +4.7% | +7.0% | +5.9% | +7.7% | +3.2% | — |
| Feb 14, 2024 | AMC | -1.00 | -0.80 | +20.0% | 8.41 | +7.0% | +15.3% | +7.4% | +3.2% | -0.6% | +2.0% | -2.0% | — |
| Dec 22, 2023 | AMC | -1.00 | -1.00 | +0.0% | 8.46 | +1.7% | +5.4% | +9.3% | +0.8% | -6.9% | -7.1% | -19.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.45 | $0.45 | +0.6% | -2.4% | -5.4% | -11.5% | -20.9% | -11.1% |
| Feb 18 | Chardan Capital | Maintains | Neutral → Neutral | — | $0.42 | $0.43 | +1.0% | -3.0% | +2.9% | -2.2% | -5.3% | -2.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.42 | $0.43 | +1.0% | -3.0% | +2.9% | -2.2% | -5.3% | -2.7% |
| Jan 5 | Chardan Capital | Maintains | Neutral → Neutral | — | $0.66 | $0.68 | +3.5% | -17.8% | -19.8% | -10.6% | -8.4% | -10.6% |
| Jan 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.58 | $0.64 | -59.4% | -58.2% | -65.7% | -66.5% | -62.7% | -61.8% |
| Dec 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.01 | $2.03 | +1.0% | -8.5% | -7.5% | -9.0% | -9.5% | -1.5% |
| Sep 30 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.06 | $1.08 | +1.9% | +0.0% | -1.9% | +0.9% | +0.0% | +2.8% |
| Sep 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.96 | $0.95 | -1.3% | +0.5% | +0.9% | +2.6% | +1.1% | +0.7% |
| Aug 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.09 | $1.04 | -4.6% | -21.9% | -20.2% | -18.3% | -18.5% | -14.2% |
| Aug 29 | Guggenheim | Downgrade | Buy → Neutral | — | $1.09 | $1.04 | -4.6% | -21.9% | -20.2% | -18.3% | -18.5% | -14.2% |
Recent Filings
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics raised capital through a registered direct offering of common stock and a concurrent private placement of warrants to purchase 16.1 million shares, expanding its equity base.
Apr 23
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics met with the FDA to appeal a complete response letter for its ONS-5010 wet AMD treatment, potentially moving toward regulatory approval after the December rejection.
Apr 21
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Outlook Therapeutics escalated an FDA disagreement over its bevacizumab biosimilar LYTENAVA through formal dispute resolution, signaling potential regulatory impasse that could delay commercialization and threaten shareholder value.
Apr 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
OTLK issued warrants at $0.25 exercise price expiring in five years, allowing investors cheap upside exposure if the stock appreciates significantly from current levels.
Mar 25
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Outlook Therapeutics secured a material partnership with Atlas Sciences, potentially expanding its commercial reach or product pipeline, which could accelerate revenue growth and reduce execution risk for shareholders.
Mar 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Outlook Therapeutics' executive change effective March 10, 2026, could signal leadership transition risks or strategic repositioning that investors should monitor for potential impacts on R&D direction and pipeline execution.
Mar 11
8-K
Unknown — 8-K Filing
Shareholders approved KPMG as auditor and supported executive compensation, indicating stable governance and investor confidence in management's pay structure at Outlook Therapeutics.
Mar 10
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics held a Type A meeting with the FDA to address deficiencies in its wet AMD drug ONS-5010, following a December 2025 complete response letter rejection of the biologics license application.
Mar 5
8-K
Outlook Therapeutics, Inc. -- 8-K Filing
Outlook Therapeutics notified Nasdaq it will attempt to cure a listing deficiency during a compliance period, potentially through a reverse stock split, or face delisting if unsuccessful.
Feb 18
8-K
Outlook Therapeutics, Inc. -- 8-K Filing
Outlook Therapeutics is expanding LYTENAVA's European presence with Austrian launch completed and additional markets planned, while advancing ONS-5010 through FDA engagement to strengthen its pipeline.
Feb 17
Data updated apr 26, 2026 6:08pm
· Source: massive.com